Who Paid My Doc
Thrombate III
Biological Hematology
NDC 13533-603-20
General payments
$244,612
Research payments
$5,173,624
Through program year 2025, $244,612 in general payments and $5,173,624 in research payments were reported against Thrombate III (Hematology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $31,059 | 213 |
| 2025 | Research | $1,947,232 | 15 |
| 2024 | General | $21,933 | 50 |
| 2024 | Research | $757,861 | 8 |
| 2023 | General | $53,287 | 187 |
| 2023 | Research | $290,312 | 4 |
| 2022 | General | $16,508 | 50 |
| 2022 | Research | $783,336 | 10 |
| 2021 | General | $23,095 | 65 |
| 2021 | Research | $273,326 | 5 |
| 2020 | General | $14,959 | 47 |
| 2020 | Research | $728,437 | 7 |
| 2019 | General | $83,771 | 204 |
| 2019 | Research | $393,120 | 33 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 22 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 22 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
816 general · 82 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.